PRLD
PRLD
NASDAQ · Biotechnology

Prelude Therapeutics Inc

$2.17
+0.15 (+7.43%)
As of Feb 8, 2:10 PM ET ·
Analyst Consensus
Strong Buy
9
Analysts
Moderate
Coverage
Buy 8 89%
Hold 1 11%
Sell 0 0%
Price Target
Analyst Price Target +334.1% upside
Low Target $6.99
Average Target $9.42
High Target $10.52
Current Price $2.17
Current
$2.17
Target
$9.42
$6.99 $9.42 avg $10.52
Scenario Analysis
Bear Case
$6.99
222.1%
Low target
Base Case
$9.42
+334.1%
Avg target
Bull Case
$10.52
+384.8%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$10.26
-78.8% from high
52-Week Low
$5.72
+-62.1% from low
Target vs 52W High
$9.42
-8.2% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%